carbon monoxide and Diffuse Cutaneous Systemic Sclerosis

carbon monoxide has been researched along with Diffuse Cutaneous Systemic Sclerosis in 9 studies

Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.

Research

Studies (9)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change From Baseline in Forced Vital Capacity (FVC) Percent Predicted to Week 52

Negative change in FVC percent predicted indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52

Change From Baseline in Modified Rodnan Skin Score (mRSS) to Week 52

The mRSS is a validated physical examination method for estimating skin thickness. It correlates with biopsy measures of collagen in the dermis and reflects prognosis and visceral involvement, especially in early disease. It is scored on 0 (normal) to 3+ (severe induration) ordinal scales over 17 body areas, with a maximum score of 51 (higher score means worse situation) and is used to categorize severity of SSc. A decrease in the mean change of mRSS shows mRSS improved. (NCT02283762)
Timeframe: Baseline to week 52

Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score to Week 52

The HAQ-DI is a composite measure from which a 'Standard Disability Index' score can be computed to assess a patient's disability level. Generally, a score of 0-1 represents mild to moderate difficulty, 1-2 moderate to severe disability and 2-3 severe to very severe disability. The HAQ-DI comprises 20 items that assess patient abilities across 8 functional activities: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item is rated on a 4-point scale: 0=Without ANY difficulty, 1=With SOME difficulty, 2=With MUCH difficulty, 3=UNABLE to do. The 8 scores of the 8 sections are summed and divided by 8. In the event that one section is not completed by a subject then the summed score would be divided by 7. The final overall HAQ-DI score ranges from 0 to 3 and positive change indicates worse health-related quality of life (HRQoL). (NCT02283762)
Timeframe: Baseline to week 52

Change From Baseline in Patient's Global Assessment Score to Week 52

The patient's global assessments (a self-report) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the patient's global assessments score indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52

Change From Baseline in Physician's Global Assessment Score to Week 52

The physician's global assessments (reported by the physician) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the physician's global assessments score indicates worsening. (NCT02283762)
Timeframe: Baseline to week 52

CRISS (American College of Rheumatology Composite Response Index for Clinical Trials) at Week 52 Reported as Number of Participants With a CRISS Probability >=0.60 or <0.60 From Baseline to Week 52

CRISS forms a composite response index consisting of SSc-related organ involvement and the following five variables: mRSS, FVC percent predicted, physician's and patient's global assessments, and HAQ-DI score (from SHAQ patient-reported outcome). The resulting index is a 2-step process that captures clinically meaningful worsening of internal organ involvement and the core variables that show change. Patients for whom the predicted CRISS probability was ≥ 0.60 were considered improved, while patients for whom the predicted probability was < 0.60 were considered not improved. (NCT02283762)
Timeframe: Week 52

Trials

1 trial available for carbon monoxide and Diffuse Cutaneous Systemic Sclerosis

Other Studies

8 other studies available for carbon monoxide and Diffuse Cutaneous Systemic Sclerosis